KUALA LUMPUR: Sheng Tai International founder and chairman Datuk Leong Sir Ley has emerged as the single largest shareholder of Yong Tai Bhd with a 23.8% stake via Domain Capital Sdn Bhd effective May 10.
First batch of Kangtai developed Covid-19 vaccine arrives in Malaysia for clinical trial | Malaysia malaymail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaymail.com Daily Mail and Mail on Sunday newspapers.
news
Private Company Says MOH Has Approved Its Phase 3 Clinical Trial Of COVID-19 Vaccine
The company, which deals in tourism and property, stated that this will help Malaysia attract huge investment as well as create job opportunities in the pharmaceutical sector.
By Sadho Ram â 28 Apr 2021, 06:07 PM
Subscribe to our Telegram channel for our latest stories and breaking news.
A property developer has obtained the Ministry of Health s approval for its Phase 3 clinical trial study of inactivated COVID-19 trial vaccines in Malaysia, as per its announcement on Bursa Malaysia
With the approval, the property developer Yong Tai Berhad â under its healthcare subsidiary YTB Healthcare Sdn Bhd (YTBH) â has become the first private company to initiate and sponsor the Phase 3 clinical trial of the COVID-19 vaccines in Malaysia.
KUALA LUMPUR (April 26): Property developer Yong Tai Bhd said its healthcare subsidiary has obtained approval from the Ministry of Health s Medical Review & Ethics Committee (MREC) for its Phase III clinical trial study of inactivated Covid-19 trial vaccines in Malaysia. The board wishes to announce that MREC had vide its letter dated April 23, approved the said Phase III Clinical Trial study to be carried out in Malaysia involving 3,000 subjects, the group said in a bourse filing today.
The health ministry has not made a statement on this matter so far.
Yong Tai said its unit, YTB Healthcare Sdn Bhds (YTBH), has formalised the Phase III clinical trial with its partner, Shenzhen Kangtai Biological Products Co Ltd (SZKT), since December last year. SZKT is a vaccine manufacturer in China.
KUALA LUMPUR (Jan 12): Promising developments on the vaccine front have stirred investor interest in companies that venture into vaccine distribution, in hopes they will be in for bumper profits.
However, it is not clear at this juncture just how much or when these companies can cash in, given just the evaluation process alone for a vaccine to be approved for distribution and use in Malaysia will take five phases. The first phase alone which is the checking of the vaccine dossiers or research documents typically takes between 90 and 120 days, according to the Ministry of Health (MoH).
When contacted, property developer Yong Tai Bhd chief executive officer Datuk Wira Boo Kuang Loon said the company expects to bring its Chinese partner s vaccine into Malaysia by the third quarter of this year, at the earliest, on obtaining approval from the MoH s National Pharmaceutical Regulatory Agency (NPRA). Any vaccines or medicines to be imported into Malaysia for use here will require NPRA